摘要
银屑病是一种慢性复发性炎症性皮肤病,现阶段实现彻底治愈具有很大挑战性。随着对银屑病发病机理的深入研究,一系列新的治疗靶点不断涌现。研究提示小分子生物制剂(Janus激酶抑制剂、磷酸二酯酶4抑制剂、蛋白激酶C抑制剂、丝裂原活化蛋白激酶抑制剂和神经生长因子受体抑制剂等)有望为银屑病的药物治疗提供更多选择。目前大部分小分子抑制剂还处于临床Ⅱ期或Ⅲ期研究阶段,其疗效和安全性等方面还需要进一步的研究。
Psoriasis is a chronic and recurrent inflammatory skin disorder,and the realization of its complete cure at current stage is very challenging. With the substantial research on the pathogenesis of psoriasis,a series of new therapeutic targets have emerged. Studies indicate that small molecule inhibitors（ Janus kinase inhibitor,phosphodiesterase 4 inhibitors,protein kinase C inhibitor,mitogen-activated protein kinase inhibitor and nerve growth factor receptor inhibitor） are expected to provide more choices for therapies of psoriasis. At present,most of the small molecule inhibitors are still at the phaseⅡ or Ⅲ of clinical trials,and their effects and safety need further investigations.
出处
《皮肤科学通报》
2018年第1期68-75,共8页
Dermatology Bulletin
基金
国家自然科学基金(81373237)
